GNLX Genelux Corp.: Bathi saben siji saham sajrone 12 wulan pungkasan

Simbol resmi perusahaan Genelux Corp. (GNLX)

Genelux Corporation brings together leading virologists developing breakthrough tumor-fighting methods within an environment of academic freedom. Anticipation of the late-stage trial results for an ovarian cancer therapy drug, with the current EPS at -0.70, serves as a key trigger. The business relies on external CROs and CMOs, fully outsourcing production and testing. This price chart clearly illustrates the price action of this asset.

Genelux Corporation (GNLX) - Bathi resik saben saham (EPS TTM) saka 11.02.2024 nganti 18.11.2026

Genelux Corporation - rincian analitis lan metrik utama (GNLX)

- rega saiki lan proyeksi nilai saham:
Analisis wiwitan perusahaan:GNLX, Genelux Corp
Produk sing diprodhuksi Genelux Corp

Genelux Corporation's development of oncolytic viruses depends on the stability of global biomaterial supply chains. Logistics disruption risks directly impact earnings per share, which this indicator measures via a rolling annual change. The metric evaluates the net profit growth rate over 12 months, allowing for the determination of the business's competitive resilience relative to the sector. The rolling period year-over-year EPS growth trend helps identify the risk of overpaying for the asset.